Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor

66Citations
Citations of this article
94Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The glucagon-like peptide-1 (GLP-1) receptor is a validated drug target for metabolic disorders. Ago-allosteric modulators are capable of acting both as agonists on their own and as efficacy enhancers of orthosteric ligands. However, the molecular details of ago-allosterism remain elusive. Here, we report three cryo-electron microscopy structures of GLP-1R bound to (i) compound 2 (an ago-allosteric modulator); (ii) compound 2 and GLP-1; and (iii) compound 2 and LY3502970 (a small molecule agonist), all in complex with heterotrimeric Gs. The structures reveal that compound 2 is covalently bonded to C347 at the cytoplasmic end of TM6 and triggers its outward movement in cooperation with the ECD whose N terminus penetrates into the GLP-1 binding site. This allows compound 2 to execute positive allosteric modulation through enhancement of both agonist binding and G protein coupling. Our findings offer insights into the structural basis of ago-allosterism at GLP-1R and may aid the design of better therapeutics.

Cite

CITATION STYLE

APA

Cong, Z., Chen, L. N., Ma, H., Zhou, Q., Zou, X., Ye, C., … Wang, M. W. (2021). Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-24058-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free